Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva J. Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos Perez, Anthony S. Stein, Daniel J. DeAngelo, Donna Neuberg, Richard M. Stone, Brian Ball, Maximilian Stahl
Topics & Concepts
MedicineInternal medicineHazard ratioOncologyVenetoclaxCytarabineNeuroblastoma RAS viral oncogene homologKRASHematopoietic stem cell transplantationTransplantationMyeloid leukemiaLeukemiaConfidence intervalCancerChronic lymphocytic leukemiaColorectal cancerAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentMultiple Myeloma Research and Treatments